Ketamine for depression: all studies (page 20)

Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm.

Asian Journal of Psychiatry June 1, 2026 Fabiola Raffone, Filippo Mazzoni, Arianna De Ciechi et al. 3 citations

Suicidal ideation and deliberate self-harm are frequent and persistent in treatment-resistant depression (TRD), particularly when comorbid borderline personality disorder (BPD) is present. Real-world evidence on antisuicidal outcomes during intranasal esketamine in this population remains limited. In this multicentre prospective observational study, 90 outpatients with TRD received intranasal...

DOI: 10.1016/j.ajp.2026.104983 Full text Esketamine Treatment-resistant depression Borderline personality disorder Self-harm +2

Ketamine infusion combined with accelerated sequential theta burst stimulation in multi-therapy-resistant bipolar depression: A case report.

Asian Journal of Psychiatry June 1, 2026 Hariprasad Ganapathy Vijayakumar, Varsha Shamanna, Harsh Pathak et al. 1 citation

Treatment resistance in bipolar depression is one of the most challenging clinical conditions to treat in psychiatry. We present a case of an elderly gentleman with chronic Multi-Therapy Resistant Bipolar Depression (MTRBD), where ketamine, a preferential NMDAR blocker on cortical GABAergic interneurons, is used adjunctively with sequential theta burst stimulation (sTBS) to achieve remission....

DOI: 10.1016/j.ajp.2026.104994 Full text Neuroplasticity Brain stimulation Depressive episode Neuromodulation +1

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

American Journal of Psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

DOI: 10.1176/appi.ajp.20250840 Full text Major depressive disorder Bipolar disorder Buprenorphine Ketamine/esketamine +1

Unveiling the role of single versus repeated low-dose ketamine in attenuating doxorubicin-induced chemobrain and depression in rats: differential modulation of neuroinflammation, phosphorylated GLT-1, SERT, DAT, and BDNF/TrkB signaling.

Neuropharmacology June 1, 2026 Nehal G. Fahmy, Nada M. Kamel, Mahmoud M. Khattab et al.

Doxorubicin (DOX), a widely utilized chemotherapeutic agent, is associated with significant adverse effects, including cognitive dysfunction (chemobrain) and depression. Ketamine (KET), the anesthetic, was off-label used as antidepressant and got FDA approval in 2019 for treatment-resistant depression management. Hence, this study investigated the therapeutic efficacy of single [KET(S)] versus...

DOI: 10.1016/j.neuropharm.2026.111055 Ketamine Depression Animals Rats, wistar +13

Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials.

JAMA Network Open June 1, 2026 Martin Walter, Christine Zu Eulenburg, Ani Damyanova et al. 1 citation

Ketamine exerts rapid antidepressant effects. However, currently available ketamine-based treatments are associated with dissociative and cardiovascular adverse effects. To evaluate the antidepressant efficacy and tolerability of KET01, a novel, oral, prolonged-release racemic ketamine tablet formulation. KET01-03 was an active-comparator, double-blind, double-dummy, crossover phase 1...

DOI: 10.1001/jamanetworkopen.2026.19121 Full text

Microbiota-Derived SCFAs Mediate the Synergistic Antidepressant Effects of Dajianzhong Decoction and Ketamine via FFAR2-NLRP3-IL-1β Signaling.

Pharmaceuticals May 31, 2026 Wenting Zhang, Xin Guo, Jiping Zhang et al.

Background: Ketamine is a rapid-acting antidepressant for major depressive disorder; however, its effects are short-lasting and associated with neurotoxic side effects. Thus, identifying strategies to prolong its antidepressant effects is of critical importance. It has been shown that Dajianzhong Decoction (DJZT) prolongs the antidepressant effects of ketamine through modulation of the gut...

DOI: 10.3390/ph19060877 Full text Depression Ketamine Djzt Ffar2–nlrp3–il-1β +2

Preliminary Non-Randomized Clinical Trial of Subcutaneous Esketamine in Treatment-Resistant Depression: Exploring Adjunctive Effects of Ketamine-Assisted Psychotherapy

medRxiv Preprint Server May 31, 2026 Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al. preprint

Background Ketamine has emerged as an effective rapid-acting treatment for treatment-resistant depression (TRD), producing significant antidepressant effects within hours of administration. Given ketamine’s capacity to induce states of heightened neuroplasticity and psychological openness, psychotherapy may represent a meaningful complement to its pharmacological effects — facilitating...

DOI: 10.64898/2026.05.31.26354555 Full text

The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications.

Journal of Pain & Palliative Care Pharmacotherapy May 29, 2026 Yogendra Singhal, Pavan Gaurav R, Sreeharsh Saji et al.

Depression is a common and serious concern in cancer patients, significantly impacting quality of life, treatment adherence, and overall prognosis. While traditional antidepressants often take weeks to exert therapeutic effects, ketamine has emerged as a potential alternative due to its rapid antidepressant action. This systematic review explores the efficacy, safety, and clinical role of...

DOI: 10.1080/15360288.2026.2679720 Full text Ketamine Depression Cancer

Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder.

Translational Psychiatry May 29, 2026 Justyna K. Hinchcliffe, Katie Kamenish, Julia M. Bartlett et al.

Affective biases shape cognitive and emotional behaviour and are important in major depressive disorder (MDD). Modulation of affective biases by the NMDA antagonist, ketamine, may underlie its antidepressant effects but not all NMDA antagonists are efficacious. Some studies suggest ketamine's efficacy involves non-NMDA mechanisms e.g. via its active metabolite HNK (2R, 6R)-hydroxynorketamine),...

DOI: 10.1038/s41398-026-04133-z Ketamine Major depressive disorder Animals Rats, sprague-dawley +7

Ketamine: Is It Superior to Midazolam for Depression?

May 27, 2026 James Phelps

A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...

DOI: 10.64239/pi-qt8704

Research